In recent years, several pharmacological agents, including GLP-1 derivatives, have been developed to treat obesity and type 2 diabetes mellitus (T2DM) with improved bioavailability [9,10]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.